血清 miR-494 的上调预示非小细胞肺癌患者预后不良。

Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.

出版信息

Cancer Biomark. 2018;21(4):763-768. doi: 10.3233/CBM-170337.

Abstract

OBJECTIVE

Emerging studies show that microRNAs (miRNAs) play a essential role in tumorigenesis. Deregulation of miR-494 is frequently observed in various human cancers including non-small cell lung cancer (NSCLC). However, little is known about the clinical significance of serum miR-494. The aim of this study was to investigate the diagnostic and prognostic value of serum miR-494 for NSCLC.

METHODS

We first compared miR-494 levels between NSCLC cell lines and lung bronchus epithelial cell line. A total of 90 NSCLC patients and 50 healthy controls were included in this study. MiR-494 levels were examined in serum samples by using real-time quantitative reverse transcription polymerase chain reactions. Association between serum miR-494 levels and the prognosis of NSCLC was further analyzed.

RESULTS

Our results showed that miR-494 was elevated in NSCLC cell lines. Serum miR-494 levels were significantly increased in patients with NSCLC compared to healthy controls. Area under receiver operating characteristic (ROC) curve was 85.4%. In addition, serum miR-494 levels decreased remarkably when patients received effective therapy. High serummiR-494 levels were significantly associated with higher incidence of lymph node metastasis, advanced clinical stage and higher histological grade. Moreover, survival analysis demonstrated that patients in the high serum miR-494 group had a poorer 5 year overall survival and disease free survival compared with the patients in the low serum miR-494 group. Multivariate analysis showed that serum miR-494 was an independent risk factor.

CONCLUSIONS

In conclusion, serum miR-494 was significantly elevated in NSCLC patients and closely correlated with poor clinical outcome, indicating that serum miR-494 might be a useful diagnostic and prognostic marker for NSCLC.

摘要

目的

新兴研究表明，微小 RNA（miRNA）在肿瘤发生中起着重要作用。miR-494 的失调在包括非小细胞肺癌（NSCLC）在内的各种人类癌症中经常观察到。然而，关于血清 miR-494 的临床意义知之甚少。本研究旨在探讨血清 miR-494 对 NSCLC 的诊断和预后价值。

方法

我们首先比较了 NSCLC 细胞系和肺支气管上皮细胞系之间的 miR-494 水平。本研究共纳入 90 例 NSCLC 患者和 50 例健康对照者。采用实时定量逆转录聚合酶链反应检测血清样本中的 miR-494 水平。进一步分析血清 miR-494 水平与 NSCLC 预后的关系。

结果

我们的结果表明，miR-494 在 NSCLC 细胞系中上调。与健康对照组相比，NSCLC 患者血清 miR-494 水平显著升高。受体操作特征曲线（ROC）下面积为 85.4%。此外，当患者接受有效治疗时，血清 miR-494 水平显著降低。高血清 miR-494 水平与更高的淋巴结转移发生率、更晚期的临床分期和更高的组织学分级显著相关。此外，生存分析表明，高血清 miR-494 组患者的 5 年总生存率和无病生存率均明显低于低血清 miR-494 组患者。多因素分析表明，血清 miR-494 是独立的危险因素。